Septerna, Inc. Increase (Decrease) in Accounts Payable
Septerna, Inc. (SEPN) reported Increase (Decrease) in Accounts Payable of -$5.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$3.50M, a 259.23% decline year-over-year.
- Septerna, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$2.30M, a 294.10% decline year-over-year.
- Septerna, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $6.07M.
- Septerna, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$2.85M, a 203.33% decline year-over-year.
- Septerna, Inc. increase (decrease) in accounts payable for fiscal 2025 was $6.60M, a 813.28% increase from fiscal 2024.
- Septerna, Inc. increase (decrease) in accounts payable for fiscal 2024 was $723.00K.
- Septerna, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$653.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$5.80M 10-Q · filed 2026-08-10 | $276.00K derived: sum of 3 quarters · filed 2026-08-10 | -$2.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$2.30M 10-Q · filed 2026-05-11 | $3.77M derived: sum of 2 quarters · filed 2026-05-11 | $920.00K derived: sum of 3 quarters · filed 2026-05-11 | $3.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.22M derived: sum of 2 quarters · filed 2026-03-09 | $5.42M derived: sum of 3 quarters · filed 2026-08-10 | $6.60M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$2.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$656.00K derived: sum of 2 quarters · filed 2026-08-10 | $530.00K 10-Q · filed 2025-11-10 | -$1.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.38M 10-Q · filed 2026-08-10 | $1.69M derived: sum of 3 quarters · filed 2026-08-10 | $4.44M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.19M 10-Q · filed 2026-05-11 | -$510.00K derived: sum of 2 quarters · filed 2026-05-11 | $2.25M derived: sum of 3 quarters · filed 2026-05-11 | $2.05M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.06M derived: sum of 2 quarters · filed 2026-03-09 | $866.00K derived: sum of 3 quarters · filed 2026-03-09 | $723.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.56M derived: sum of 2 quarters · filed 2025-11-10 | $2.42M 10-Q · filed 2025-11-10 | $2.90M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$340.00K 10-Q · filed 2025-08-11 | $138.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$143.00K 10-Q · filed 2025-05-15 | $335.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$653.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$1.13M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |